Thawing market heats up: Biocision expands cell therapy tech offering

By Gareth Macdonald

- Last updated on GMT

Thawing market heats up: Biocision expands cell therapy tech offering

Related tags Stem cell

Biocision has revamped its cell thawing platform to accommodate larger vial sizes and started developing an automated system for cell therapies in cryopreservation bags.

The California, US-based technology developer  has launched new versions of its ThawStar system that are designed to thaw cell therapies preserved in 1.5mL cryogenic vials and 6mL AT-Closed vials developed by Belgian firm Aseptic Technologies S.A.

The developmental bag-scale thawing system is designed to handle larger volume cell therapies, which is an increasing area of demand for manufacturers with trial and commercial stage products according to Biocision CEO, Rolf Ehrhardt.

Providing a translational thawing platform that accommodates small- and large-volume closed system formats allows our customers to adopt it early in the research and development phase and have confidence in knowing that it can be seamlessly incorporated into commercial manufacturing, and point of care​.”

Sensitive cells

Thawing is a hot topic for cell therapy developers. Most biopharmaceutical products are sensitive to temperature changes, but personalized cell therapies are particularly susceptible.

As a result cell therapies are usually frozen at the manufacturing facility before being shipped to the clinic for administration back to the patient.

But protecting these sensitive and usually irreplaceable treatments is not enough according to Biocision, which says induced pluripotent stem cells (IPSC), chimeric antigen receptor T- cells (CAR-T) and “natural killer” (NK) cells can also be damaged by the thawing process.

The common method of thawing cryopreserved cells and cell-based therapeutics involves sequentially placing frozen vials or bags into a warm water bath; a method fraught with challenges that leaves the cells and therapies at risk of contamination and potentially jeopardizes drug efficacy and safety​.”

Biocision's system is designed to eliminate water bath thawing using technology that senses the initial starting temperature and phase change initiation and customizes the thaw for each vial.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars